Go Pro
NASDAQ:MSLE

Satellos Bioscience Q1 2026 Earnings Report

$8.44 +0.09 (+1.09%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Satellos Bioscience EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Satellos Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Satellos Bioscience Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Satellos Bioscience Earnings Headlines

HC Wainwright Brokers Increase Earnings Estimates for MSLE
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel
See More Satellos Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email.

About Satellos Bioscience

Satellos Bioscience (NASDAQ:MSLE) is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.

View Satellos Bioscience Profile